证券研究报告 | 策略点评 2025 年 05 月 20 日 投资要点 分析师：孟之绪 执业编号：S0300524080001 电话： 邮箱：mengzhixu@ykzq.com 投资策略研究 粤开市场日报-20250520 今日关注 指数涨跌情况：今日 A 股主要指数多数上涨。截止收盘，沪指涨 0.38%，收报 3380.48 点；深证成指涨 0.77%，收报 10249.17 点；科创 50 涨 0.24%，收报 997.68 点；创业板指涨 0.77%，收报 2048.46 点。总体上，全天个股涨多跌 少，Wind 数据显示，全市场 3836 只个股上涨，1376 只个股下跌，199 只个股 收平。沪深两市今日成交额合计 11698 亿元，较上个交易日放量 832.34 亿元。 行业涨跌情况：今日申万一级行业除国防军工、煤炭、钢铁、房地产下跌外， 其余全部上涨，美容护理、综合、传媒、家用电器、医药生物、轻工制造等 行业领涨。 板块涨跌情况：今日涨幅居前概念板块为宠物经济、动物保健精选、三胎、 谷子经济、培育钻石、饲料精选、超硬材料、水电、医美、小红书平台、仿 制药、黄金珠宝、首发经济、央企汽车、生物科技 ...

Core Viewpoint - The company, Jinhe Biology, reported a strong performance in the first quarter of 2025, with significant growth in revenue and net profit, driven primarily by its veterinary chemical products, particularly the sales of its key product, Jinmeisu [4][12]. Revenue and Profit Growth - In Q1 2025, the company achieved an operating income of 625.15 million yuan, representing a year-on-year increase of 20.35% [4][12]. - The net profit attributable to shareholders was 51.12 million yuan, up 13.23% year-on-year [4][12]. - The gross profit margin stood at 35.78% [12]. Product Performance - Revenue from veterinary chemical products increased by 21.47% year-on-year, with Jinmeisu being a major contributor, especially in the U.S. market, which reached a historical high [2]. - The company plans to enhance its product offerings with the full production of a new factory in 2025, which will produce Jinmeisu, Tetracycline, and Strongly Mycin, thereby extending its product line [2]. Research and Development - R&D expenses grew by 27.03% in 2024, indicating a strong commitment to innovation [3]. - The company is focusing on expanding the application of Jinmeisu and has received approval for its use in additional target animals, including sheep [3]. Market Outlook - The global animal health industry is expected to continue growing, with the domestic market showing significant potential, as evidenced by a compound annual growth rate of 8.43% in the domestic veterinary drug market from 2019 to 2023 [5][11]. - The company is optimistic about the future, particularly in the veterinary biological products market and the pet market, which is also expanding [6][11]. Strategic Initiatives - The company is enhancing its collaboration with Shanghai Jiao Tong University to leverage synthetic biology for product development and innovation [8]. - Plans are in place to expand the pet health business, with a focus on both chemical and vaccine products [8]. Competitive Position - The company has established a strong presence in the overseas market, with 60-70% of its chemical products sold internationally, particularly in the U.S. [10]. - The company aims to strengthen its market position by enhancing customer satisfaction and expanding its product offerings in international markets [10].

第一节 重要提示 1、本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到www.sse.com.cn网站仔细阅读年度报告全文。 登录新浪财经APP 搜索【信披】查看更多考评等级 2、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 3、公司全体董事出席董事会会议。 公司拟以未来实施权益分派方案时股权登记日的公司总股本扣除股份回购专户中股份数量后的股份总数 为基数，向全体股东每10股派送现金红利0.30元（含税）。此预案尚需经公司2024年年度股东大会审议 批准。 第二节 公司基本情况 1、公司简介 ■ 2、报告期公司主要业务简介 根据《上市公司行业统计分类指引》（2023年修订版），公司所处行业为医药制造业，细分子行业为兽 用药品制造业。兽用药品行业又称"动物保健行业"（简称"动保行业"），国内动保市场主要包括兽用生 物制品、兽用化学药品、中兽药三大细分市场，其中兽用生物制品市场以动物疫苗为主，是动保市场中 增速最快的细分领域。动保行业需求主要由下游养殖行 ...